Summary
This document is an amendment to Gilead Sciences, Inc.'s 2018 Form 10-K filing, primarily detailing the exhibits and financial statement schedules included in the original report. For investors, this filing doesn't introduce new financial performance data or strategic updates for the 2018 fiscal year itself, but rather provides a comprehensive list of corporate governance documents, material contracts, and compensation plans. The included exhibits cover the company's charter and bylaws, various senior note indentures, a wide array of equity and deferred compensation plans for employees and directors, severance and bonus plans, significant license and collaboration agreements (including those related to Kite Pharma and Japan Tobacco), and subsidiary information. The certifications from the CEO and CFO reaffirm the accuracy of the original 10-K filing. Investors should refer to the original February 26, 2019 10-K filing for detailed financial performance, results of operations, and forward-looking statements. While this amendment doesn't contain new operational or financial results, it underscores the robust legal and contractual framework governing Gilead. The numerous exhibits related to employee and executive compensation, as well as significant partnership and licensing agreements, are key to understanding the company's long-term structure and strategic collaborations. The inclusion of detailed indentures for senior notes also provides insight into the company's debt obligations. Investors seeking a current view of Gilead's business strategy and financial health should consult the most recent filings and the original 10-K for the 2018 fiscal year.
Financial Highlights
57 data points| Revenue | $22.13B |
| Cost of Revenue | $4.85B |
| Gross Profit | $17.27B |
| R&D Expenses | $5.02B |
| SG&A Expenses | $4.06B |
| Operating Expenses | $13.93B |
| Operating Income | $8.20B |
| Interest Expense | $1.08B |
| Net Income | $5.46B |
| EPS (Basic) | $4.20 |
| EPS (Diluted) | $4.17 |
| Shares Outstanding (Basic) | 1.30B |
| Shares Outstanding (Diluted) | 1.31B |
Key Highlights
- 1This filing is an amendment to Gilead's 2018 10-K, primarily listing incorporated and newly filed exhibits, not a new financial performance report.
- 2The exhibits include key corporate governance documents such as the Restated Certificate of Incorporation and Amended and Restated Bylaws.
- 3A comprehensive list of senior note indentures demonstrates Gilead's structured approach to debt financing.
- 4Numerous exhibits detail various equity incentive plans, deferred compensation plans, and bonus plans, reflecting the company's compensation structure for employees and executives.
- 5Significant license and collaboration agreements are listed, including those with Japan Tobacco Inc. and Kite Pharma, highlighting strategic partnerships.
- 6The filing includes the CEO and CFO certifications confirming the accuracy of the original 10-K filing.
- 7Subsidiary information and consent of independent registered public accounting firm are also provided as exhibits.